This study involves taking a study drug called
TAS-117. The overall goal of this study is to see if TAS-117 is a possible
treatment for advanced cancers with germline mutations in the PTEN gene.
The purpose of this study
is to determine the highest safe dose of abemaciclib in patients with relapsed
or treatment refractory solid tumors given in combination with the chemotherapy
drugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide
(Part B).
The purpose of this research study is to evaluate the side effects of using proton radiation therapy for kidney tumors.  Proton radiation can limit the radiation exposure of normal tissues and decrease the side effects from radiation compared to the current standard methods of treating kidney tumors with x-ray radiation. Proton radiation has proven to be as effective at treating tumors as current standard radiation methods in other disease sites, but it has not been used for treatment of kidney tumors in children.
This study involves taking a study drug called ramucirumab.
The overall goal of this study is to see how effective ramucirumab is when
given in combination with cyclophosphamide and vinorelbine in children and
young adults with desmoplastic small round cell tumor (DSRCT).
This study involves taking a study drug called
ramucirumab. The overall goal of this study is to see how effective ramucirumab
is when given in combination with gemcitabine and docetaxel in children
and young adults with synovial sarcoma.
This study involves taking a study drug called CUDC-907. CUDC-907 is an oral drug that blocks certain
proteins in tumor cells; these proteins may be important in the growth of some
cancers. The overall goals of this study are to evaluate the side effects and
benefits of CUDC-907 in patients with relapsed or treatment refractory solid
tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for
children and adolescents. This study
will also look at the levels of CUDC-907 in the blood over time after a dose.